ReviewNeuromolecular medicine2012
Sleep disturbances in Alzheimer's and Parkinson's diseases.
Review in Neuromolecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Efficacy of non-pharmacological interventions for sleep quality in Parkinson's disease: a systematic review and network meta-analysis.Frontiers in neuroscience · 2024Pooled it
- Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Pooled it
- Tooth loss as a factor associated with deterioration of quality and increase in sleep duration: analysis of the 2016-2017 Chilean National Health Survey.BMC oral health · 2026Article
- Hypothalamic MCH neurons links tau pathology to sleep disruption.bioRxiv : the preprint server for biology · 2026Article
- Glial cytokine modulation improves sleep and circadian disruption in female SAA knock-in mice of Alzheimer's-related pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Exploring the feasibility of modeling next-day fatigue and sleepiness using digital sleep tracker data in neurodegenerative and immune-mediated inflammatory diseases.Frontiers in digital health · 2026Article
- Sleep Disorders in Neurodegenerative Diseases with Dementia: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Butyrate improves abnormal sleep architecture in a Parkinson's disease mouse model via BDNF/TrkB signaling.NPJ Parkinson's disease · 2025Article
- Transforming Sleep Monitoring: Review of Wearable and Remote Devices Advancing Home Polysomnography and Their Role in Predicting Neurological Disorders.Biosensors · 2025Review
- Multimodal state-dependent connectivity analysis of arousal and autonomic centers in the brainstem and basal forebrain.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Sex differences in sleep deficits in mice with an autism-linked Shank3 mutation.Biology of sex differences · 2024Article
- Daytime napping and the incidence of Parkinson's disease: a prospective cohort study with Mendelian randomization.BMC medicine · 2024Article
- Proprioceptive and olfactory deficits in individuals with Parkinson disease and mild cognitive impairment.Acta neurologica Belgica · 2024Article
- The effect of intensive rehabilitation treatment on sleep disorder in children with motor delays.BMC pediatrics · 2023Article
- Parkinson's Disease: A Narrative Review on Potential Molecular Mechanisms of Sleep Disturbances, REM Behavior Disorder, and Melatonin.Brain sciences · 2023Review
- Associations of Late-Life Sleep Medication Use With Incident Dementia in the Atherosclerosis Risk in Communities Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimer's disease and longevity in an Italian population.GeroScience · 2022Article
- Abnormalities in the Fractional Amplitude of Low-Frequency Fluctuation and Functional Connectivity in Parkinson's Disease With Excessive Daytime Sleepiness.Frontiers in aging neuroscience · 2022Article
- Boosting Recovery During Sleep by Means of Auditory Stimulation.Frontiers in neuroscience · 2022Article
- Cerebral metabolic rate of oxygen during transition from wakefulness to sleep measured with high temporal resolution OxFlow MRI with concurrent EEG.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders and exact a burden on our society greater than cardiovascular disease and cancer combined. While cognitive and motor symptoms are used to define AD and PD, respectively, patients with both disorders exhibit sleep disturbances including insomnia, hypersomnia and excessive daytime napping. The molecular basis of perturbed sleep in AD and PD may involve damage to hypothalamic and brainstem nuclei that control sleep-wake cycles. Perturbations in neurotransmitter and hormone signaling (e.g., serotonin, norepinephrine and melatonin) and the neurotrophic factor BDNF likely contribute to the disease process. Abnormal accumulations of neurotoxic forms of amyloid β-peptide, tau and α-synuclein occur in brain regions involved in the regulation of sleep in AD and PD patients, and are sufficient to cause sleep disturbances in animal models of these neurodegenerative disorders. Disturbed regulation of sleep often occurs early in the course of AD and PD, and may contribute to the cognitive and motor symptoms. Treatments that target signaling pathways that control sleep have been shown to retard the disease process in animal models of AD and PD, suggesting a potential for such interventions in humans at risk for or in the early stages of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.